SCHEMBL7879945

SCHEMBL7879945

CN(C(=N)N)C(=O)c1cc2ccc(Oc3ccc(CN)s3)cc2[nH]1

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.41
MEN1 O00255 3/20 0.41
RXFP1 Q9HBX9 2/20 0.41
AR P10275 3/20 0.39
PLG P00747 1/20 0.36
PLAU P00749 1/20 0.36
FLT3 P36888 3/20 0.35
PDGFRB P09619 1/20 0.35
PDGFRA P16234 1/20 0.35
NPC1 O15118 4/20 0.33
RAB9A P51151 4/20 0.33
ITGB3 P05106 1/20 0.32
ITGA2B P08514 1/20 0.32
HRH4 Q9H3N8 1/20 0.32
CA2 P00918 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7884567 0.91 KMT2A (0.43) KMT2AMEN1RXFP1ARPLG
SCHEMBL7880987 0.89 KMT2A (0.41) KMT2AMEN1RXFP1ARPLG
SCHEMBL7884774 0.87 KMT2A (0.41) KMT2AMEN1RXFP1ARPLG
SCHEMBL7943749 0.86 FLT3 (0.39) KMT2AMEN1RXFP1ARPLG
SCHEMBL7881580 0.86 MEN1 (0.41) KMT2AMEN1RXFP1ARPLG
SCHEMBL7884361 0.84 RHEB (0.33) FLT3
SCHEMBL7873484 0.83 KMT2A (0.42) KMT2AMEN1RXFP1ARPLG
SCHEMBL7881254 0.83 MEN1 (0.38) KMT2AMEN1RXFP1ARPLG
SCHEMBL7881184 0.83 KMT2A (0.47) KMT2AMEN1RXFP1PLGPLAU
SCHEMBL7880966 0.82 AR (0.44) KMT2AMEN1RXFP1ARPLG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6248772-B1 HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2001-06-19 US disclosed
US-6169107-B1 USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS SUMITOMO PHARMACEUTICAL CO., LTD. (JP) 2001-01-02 US disclosed
EP-0708091-A2 Indoloylguanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1996-04-24 EP disclosed